SCHEMBL2300655

SCHEMBL2300655

COc1cccc(OS(=O)(=O)c2ccc(N3CCNC3=O)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 8/20 0.50
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPT P10636 1/20 0.44
CTSG P08311 1/20 0.42
CMA1 P23946 1/20 0.42
ROCK2 O75116 1/20 0.41
MAOB P27338 1/20 0.41
ADRB1 P08588 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235366 0.94 CYP1A1 (0.47) CYP1A1GAAKMT2AATMALDH1A1
SCHEMBL2302728 0.91 CYP1A1 (0.58) CYP1A1GAASMN1; SMN2LMNAHTT
SCHEMBL12353905 0.88 ALDH1A1 (0.51) CYP1A1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL2234141 0.87 GAA (0.61) CYP1A1GAASMN1; SMN2LMNAHTT
SCHEMBL2302983 0.87 GAA (0.61) CYP1A1GAASMN1; SMN2LMNAHTT
SCHEMBL2300168 0.87 CYP1A1 (0.48) CYP1A1GAAKMT2AALDH1A1SMN1; SMN2
SCHEMBL2301973 0.86 ALDH1A1 (0.45) CYP1A1GAAKMT2AATMALDH1A1
SCHEMBL2299333 0.86 ALDH1A1 (0.45) CYP1A1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL14708703 0.86 CYP1A1 (0.53) CYP1A1GAAKMT2AATMSMN1; SMN2
SCHEMBL2304868 0.85 CYP1A1 (0.59) CYP1A1GAAKMT2AATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 CYP1A1 1777/4885GAA 3894/4885KMT2A 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.